{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174954","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.073625+00:00","generated_at":"2026-05-17T18:06:57.161819+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks","bullets":["FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.","Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.","Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).","Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.","NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174954","json":"https://secwatch.observer/filing/0001193125-25-174954.json","markdown":"https://secwatch.observer/filing/0001193125-25-174954.md","text":"https://secwatch.observer/filing/0001193125-25-174954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/0001193125-25-174954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:06:57.161819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}